ES2533566T3 - Diana diagnóstica y terapéutica para enfermedades autoinmunitarias y sus usos - Google Patents

Diana diagnóstica y terapéutica para enfermedades autoinmunitarias y sus usos Download PDF

Info

Publication number
ES2533566T3
ES2533566T3 ES07870089.5T ES07870089T ES2533566T3 ES 2533566 T3 ES2533566 T3 ES 2533566T3 ES 07870089 T ES07870089 T ES 07870089T ES 2533566 T3 ES2533566 T3 ES 2533566T3
Authority
ES
Spain
Prior art keywords
znt8
antibodies
protein
fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07870089.5T
Other languages
English (en)
Spanish (es)
Inventor
John C. Hutton
Janet M. Wenzlau
Jan Jensen
Howard Davidson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
University of Colorado Colorado Springs
Original Assignee
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System, University of Colorado Colorado Springs filed Critical University of Colorado System
Application granted granted Critical
Publication of ES2533566T3 publication Critical patent/ES2533566T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
ES07870089.5T 2006-12-29 2007-12-28 Diana diagnóstica y terapéutica para enfermedades autoinmunitarias y sus usos Active ES2533566T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88281506P 2006-12-29 2006-12-29
US882815P 2006-12-29
PCT/US2007/089125 WO2008083331A2 (en) 2006-12-29 2007-12-28 Diagnostic and therapeutic target for autoimmune diseases and uses thereof

Publications (1)

Publication Number Publication Date
ES2533566T3 true ES2533566T3 (es) 2015-04-13

Family

ID=39589229

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07870089.5T Active ES2533566T3 (es) 2006-12-29 2007-12-28 Diana diagnóstica y terapéutica para enfermedades autoinmunitarias y sus usos

Country Status (8)

Country Link
US (1) US9023984B2 (enExample)
EP (1) EP2118309B1 (enExample)
JP (1) JP5694668B2 (enExample)
CN (1) CN101646781B (enExample)
DK (1) DK2118309T3 (enExample)
ES (1) ES2533566T3 (enExample)
PL (1) PL2118309T3 (enExample)
WO (1) WO2008083331A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2486122A (en) * 2009-09-18 2012-06-06 Univ California Methods for detecting autodigestion
CN102060910B (zh) * 2010-11-12 2012-11-21 中国人民解放军第三军医大学 锌转运蛋白8的hla-a＊0201限制性ctl表位及其应用
KR20250020688A (ko) * 2011-04-29 2025-02-11 셀렉타 바이오사이언시즈, 인크. 항체 반응을 감소시키기 위한 관용원성 합성 나노운반체
US20140271701A1 (en) 2011-10-26 2014-09-18 Universita' Degli Studi Di Sassari Use of mycobacterium avium paratuberculosis peptides to diagnose type 1 diabetes
CN103177198B (zh) * 2011-12-26 2016-11-23 深圳华大基因科技服务有限公司 一种蛋白质鉴定方法
IN2014DN09410A (enExample) 2012-04-13 2015-07-17 Diabetomics Llc
CN102967704B (zh) * 2012-11-26 2014-05-14 深圳市伯劳特生物制品有限公司 一种用于糖尿病自身抗体6项联检试剂盒
US20160025744A1 (en) * 2013-03-14 2016-01-28 The Board Of Trustees Of The Leland Stanford Junior University Plasmonic substrate for multiplex assessment of type 1 diabetes
MX2021005697A (es) 2013-05-03 2021-07-07 Selecta Biosciences Inc Suministro de inmunosupresores que tienen una vida efectiva especificada, farmacodinamica y antigeno para la induccion de tolerancia inmunitaria.
KR102523912B1 (ko) 2013-06-11 2023-04-21 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 SC-β 세포 및 조성물 그리고 그 생성 방법
CN106535926B (zh) * 2014-06-04 2022-02-01 戴尔米德医疗公司 用于基于抗原的疗法的新型组合物
KR101482908B1 (ko) 2014-07-25 2015-01-15 충남대학교산학협력단 간질중첩증 진단용 바이오마커 조성물
CN106714826A (zh) 2014-09-07 2017-05-24 西莱克塔生物科技公司 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物
EP4374863A3 (en) 2014-12-18 2024-09-04 President and Fellows of Harvard College Methods for generating stem cell-derived beta cells and uses thereof
CN113234661A (zh) 2014-12-18 2021-08-10 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
US10443042B2 (en) 2014-12-18 2019-10-15 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
GB201510056D0 (en) * 2015-06-10 2015-07-22 King S College London Multi-peptide composition
US10542961B2 (en) 2015-06-15 2020-01-28 The Research Foundation For The State University Of New York System and method for infrasonic cardiac monitoring
US20170082619A1 (en) 2015-09-23 2017-03-23 One Lambda, Inc. Methods of Detecting Alloantibodies Using HLA and Non-HLA Antigens
CN106084051B (zh) * 2016-02-17 2018-03-02 张梅 一种ZnT8特异性单链抗体scFv‑C27及其应用
CN106084043B (zh) * 2016-02-17 2018-03-02 张梅 一种ZnT8特异性单链抗体scFv‑C22及其应用
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
CN106771233A (zh) * 2016-12-05 2017-05-31 上海良润生物医药科技有限公司 ZnT8A自身抗体检测试剂盒
CN110612122A (zh) 2017-03-11 2019-12-24 西莱克塔生物科技公司 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
MX2020004939A (es) 2017-11-15 2020-11-11 Semma Therapeutics Inc Fabricacion de composiciones de celulas islote y metodos de uso de las mismas.
CN108414766A (zh) * 2018-01-29 2018-08-17 上海良润生物医药科技有限公司 用于定量检测糖尿病自身抗体的试剂盒及其应用
AU2019320072A1 (en) 2018-08-10 2021-02-25 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
EP3837286A4 (en) 2018-08-16 2022-08-10 The Johns Hopkins University ANTIBODIES TO HUMAN ZNT8
CN109628462B (zh) * 2018-12-13 2021-02-19 宁波大学 一种水稻根系伸长控制基因OsKSR7及编码的蛋白质
CN109734793B (zh) * 2019-03-14 2022-12-02 深圳市药品检验研究院（深圳市医疗器械检测中心） 一种ZnT8重组蛋白及其制备方法和应用
US12366570B2 (en) 2019-10-01 2025-07-22 The Johns Hopkins University Cell-based ZNT8 assay
CN111579791A (zh) * 2020-04-30 2020-08-25 江苏省人民医院（南京医科大学第一附属医院） 一种锌转运体8胰岛自身抗体的电化学发光检测试剂盒
CN113999841A (zh) * 2021-09-16 2022-02-01 江苏省人民医院（南京医科大学第一附属医院） 蛋白质支架oval100及其在放射配体法中的应用
CN116589589B (zh) * 2023-03-24 2024-10-22 深圳市昭蓝生物科技有限公司 糖尿病检测的质控品及其制备方法和用途
CN117031014A (zh) * 2023-08-14 2023-11-10 陕西脉元生物科技有限公司 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒
CN120714599B (zh) * 2025-08-28 2025-10-31 江苏集萃医工交叉技术研究所有限公司 一种血清bicc1天然蛋白的高效提取保存方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2043472A1 (en) 1990-06-04 1991-12-05 Mitsutaka Miyabayashi Electrode for secondary battery
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US20020082207A1 (en) 2000-06-07 2002-06-27 Hirst Shannon K. Compositions and methods for the therapy and diagnosis of pancreatic cancer
FR2847263B1 (fr) 2002-11-18 2006-01-13 Commissariat Energie Atomique Polynucleotide specifique de la cellule pancreatique beta des ilots de langerhans

Also Published As

Publication number Publication date
PL2118309T3 (pl) 2015-07-31
EP2118309B1 (en) 2015-01-28
US9023984B2 (en) 2015-05-05
JP5694668B2 (ja) 2015-04-01
DK2118309T3 (en) 2015-03-30
JP2010514805A (ja) 2010-05-06
WO2008083331A2 (en) 2008-07-10
EP2118309A4 (en) 2010-06-02
CN101646781B (zh) 2016-06-22
WO2008083331A3 (en) 2008-11-13
CN101646781A (zh) 2010-02-10
US20100143374A1 (en) 2010-06-10
EP2118309A2 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
ES2533566T3 (es) Diana diagnóstica y terapéutica para enfermedades autoinmunitarias y sus usos
Schranz et al. Immunology in diabetes: an update
Pugliese Autoreactive T cells in type 1 diabetes
Roep et al. Antigen targets of type 1 diabetes autoimmunity
Leslie et al. Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes
Lernmark Glutamic acid decarboxylase–gene to antigen to disease
Wenzlau et al. Novel antigens in type 1 diabetes: the importance of ZnT8
Towns et al. GAD65 autoantibodies and its role as biomarker of Type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA)
Zhang et al. Prediction and prevention of Type 1 diabetes mellitus
US20130115218A1 (en) Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
Brezar et al. Beyond the hormone: insulin as an autoimmune target in type 1 diabetes
Yeo et al. Circulating β cell-specific CD8+ T cells restricted by high-risk HLA class I molecules show antigen experience in children with and at risk of type 1 diabetes
US20130189284A1 (en) Antibodies with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
Nayak et al. ZnT8-reactive T cells are weakly pathogenic in NOD mice but can participate in diabetes under inflammatory conditions
Wu et al. Pathogenic mechanisms of disease in idiopathic inflammatory myopathies: autoantibodies as clues
Dwyer et al. Antigen-specific T cell responses in autoimmune diabetes
US10024854B2 (en) Method for detecting and purifying pancreatic beta cells
Potter et al. The molecular specificity of insulin autoantibodies
Desai et al. Autoimmune diabetes in adults: lessons from the UKPDS
Smith et al. The role of B lymphocytes in type 1 diabetes
Hänninen et al. Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff‐person syndrome but without type 1 diabetes
James et al. Immunology of Diabetes Society T‐Cell Workshop: HLA class II tetramer‐directed epitope validation initiative
Lin et al. A multivalent vaccine for type 1 diabetes skews T cell subsets to Th2 phenotype in NOD mice
US20060014941A1 (en) Isolated T lymphocyte receptors specific for human autoantigens complexed with human MHC molecules and methods of making and using same
Weenink et al. Autoantibodies in diabetes